Kevin Ju­dice plays DiCE, piv­ot­ing from a $60M raise straight to the big S-1 fil­ing

These days, it’s not hard to tell when a biotech is get­ting ready to launch an IPO.

Ear­li­er this week, Kevin Ju­dice tipped his hand when DiCE Mol­e­cules put out a terse re­lease about rais­ing $60 mil­lion. An en­thu­si­as­tic ad­vo­cate of his work on an oral IL-17 drug to ri­val Cosen­tyx and Taltz, a pair of block­buster an­ti­bod­ies, Ju­dice wouldn’t have passed up on a chance to spot­light the com­pa­ny. So his no­table si­lence made it pret­ty clear that an IPO was in the works.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER